CTOR - NASDAQ

Citius Oncology, Inc.

CTOR·NASDAQ

$0.78

-0.064%

HealthcareDrug Manufacturers - General

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$72.48M

EPS-0.3400

P/E Ratio-2.29

Earnings Date08/18/2026

No Revenue Data

CTOR has not reported any revenue values in the available annual periods.

-24.76M

Net Income

17%

3Y+128.0%

5Y+244747.0%

10Y+244747.0%

-5.49M

Operating Cash Flow

-4447%

3Y+11349.0%

5Y+11349.0%

10Y+11349.0%

Citius Oncology, Inc. Profit Bridge

CTOR · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (0.00)

Gross Profit0.00

Operating Expenses

Operating Expenses (23.52M)

Operating Income-23.52M

Other Income & Taxes

Interest Expense (218.03K)

Other Income/Expense-181.66K

Pretax Income-23.70M

Income Tax (1.06M)

Net Income-24.76M

Net Income

-24.76M

Profitability Analysis

Citius Oncology, Inc. Income Statement

CTOR • NASDAQ

Citius Oncology, Inc. Income Statement	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Dec 2021
REVENUE
GROSS PROFIT
OPERATING INCOME
Operating Expenses	(23.5M)	(20.6M)	(12.1M)	(9.7M)	(0.0)
Selling, General & Administrative	(17.1M)	(15.6M)	(7.9M)	(2.9M)	(0.0)
Research & Development	(6.4M)	(4.9M)	(4.2M)	(6.9M)	(0.0)
Operating Income	-23.5M	-20.6M	-12.1M	-9.7M	0.0
PRE-TAX INCOME
Interest Expense	(218K)	(0.0)	(0.0)	(0.0)	(0.0)
Net Interest Income	-181.7K	0.0	0.0	0.0	0.0
Total Other Income Expenses Net	-181.7K	0.0	0.0	0.0	-10.1K
Income Before Tax	-23.7M	-20.6M	-12.1M	-9.7M	-10.1K
NET INCOME
Income Tax Expense	(1.1M)	(576K)	(576K)	(1.2M)	(0.0)
Net Income	-24.8M	-21.1M	-12.7M	-10.9M	-10.1K

SEC Filings

CTOR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 01, 2026	June 01, 2026	2026	View Filing
S-3 S-3 N/A	May 29, 2026	May 29, 2026		View Filing
8-K 8-K 2026 N/A	May 15, 2026	May 15, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 15, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 22, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 31, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 10, 2026	March 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 04, 2026	March 04, 2026	2026	View Filing

Showing 1 to 10 of 86 filings

Related Guides

Blog Categories

Continue your CTOR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.